[Periprocedural management of anticoagulation in patients undergoing atrial fibrillation ablation].
Catheter ablation of atrial fibrillation (AF) has been increasingly performed and has become a standard of care treatment option for drug-refractory symptomatic patients. However, this procedure has been associated with major complications, like thromboembolic or bleeding events. Optimal periprocedural anticoagulation strategy is essential for minimizing these complications. In this article, we review current anticoagulation strategies, including use of oral anticoagulation with Vit-K-Antagonists, as well as use of direct oral anticoagulants in the periprocedural settings of AF ablation.
C-I
CI
Park
E
E
Pruvot
A
A
Jadidi
H
H
Lehrmann
R
R
Weber
T
T
Arentz
M
M
Zimmermann
D000925:Anticoagulants / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000601:surgery*; D001562:Benzimidazoles / Q000627:therapeutic use; D017115:Catheter Ablation / Q000009:adverse effects; D000069604:Dabigatran; D006801:Humans; D009025:Morpholines / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D000069552:Rivaroxaban; D013876:Thiophenes / Q000627:therapeutic use; D013923:Thromboembolism / Q000209:etiology / Q000517:prevention & control*; D015091:beta-Alanine / Q000031:analogs & derivatives / Q000627:therapeutic use
D000925:Anticoagulants; D001562:Benzimidazoles; D009025:Morpholines; D013876:Thiophenes; D015091:beta-Alanine; D000069552:Rivaroxaban; D000069604:Dabigatran